Your browser is no longer supported. Please, upgrade your browser.
aTyr Pharma, Inc.
Index- P/E- EPS (ttm)-2.29 Insider Own0.20% Shs Outstand16.13M Perf Week-2.07%
Market Cap220.07M Forward P/E- EPS next Y-1.96 Insider Trans- Shs Float15.30M Perf Month-31.65%
Income-29.10M PEG- EPS next Q-0.60 Inst Own60.00% Short Float10.20% Perf Quarter93.42%
Sales2.20M P/S100.03 EPS this Y74.80% Inst Trans84.15% Short Ratio0.29 Perf Half Y104.07%
Book/sh2.54 P/B3.36 EPS next Y1.80% ROA-63.00% Target Price19.71 Perf Year158.48%
Cash/sh1.71 P/C4.99 EPS next 5Y13.00% ROE-75.30% 52W Range2.93 - 13.10 Perf YTD119.85%
Dividend- P/FCF- EPS past 5Y42.60% ROI- 52W High-34.89% Beta1.54
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low191.13% ATR0.78
Employees43 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)48.34 Volatility3.82% 7.43%
OptionableYes Debt/Eq0.00 EPS Q/Q6.50% Profit Margin- Rel Volume0.08 Prev Close8.57
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume5.35M Price8.53
Recom1.80 SMA20-5.46% SMA5011.71% SMA20061.07% Volume423,526 Change-0.47%
Oct-12-21Initiated RBC Capital Mkts Outperform $22
Sep-21-21Initiated Piper Sandler Overweight $19
May-10-21Initiated Laidlaw Buy $18
Aug-17-20Upgrade H.C. Wainwright Neutral → Buy $13
Mar-04-20Initiated ROTH Capital Buy $15
Mar-02-20Initiated Oppenheimer Outperform $8
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Sep-07-17Initiated Piper Jaffray Overweight $7
Dec-13-16Downgrade JP Morgan Overweight → Neutral
Dec-16-15Initiated Citigroup Neutral
Jun-01-15Initiated JP Morgan Overweight $44
Jun-01-15Initiated Citigroup Buy $32
Oct-14-21 02:08PM  
Oct-11-21 08:40AM  
Oct-06-21 08:00AM  
Oct-01-21 08:01AM  
Sep-20-21 04:07PM  
Sep-16-21 04:01PM  
Sep-15-21 04:01PM  
Sep-14-21 05:43PM  
Sep-13-21 07:30AM  
Aug-23-21 09:53AM  
Aug-10-21 05:15PM  
Aug-09-21 08:00AM  
Aug-03-21 08:00AM  
Aug-02-21 05:03AM  
Jul-29-21 04:05PM  
Jul-27-21 02:00AM  
Jul-08-21 08:00AM  
Jun-30-21 10:26AM  
Jun-23-21 08:00AM  
Jun-21-21 02:00AM  
Jun-10-21 04:30PM  
Jun-09-21 12:05PM  
Jun-02-21 04:58AM  
May-28-21 12:20PM  
May-25-21 08:00AM  
May-19-21 08:00AM  
May-13-21 05:20PM  
May-12-21 08:00AM  
May-11-21 08:00AM  
May-06-21 08:00AM  
May-04-21 03:00PM  
Apr-20-21 08:00AM  
Apr-14-21 09:42AM  
Apr-09-21 08:00AM  
Apr-08-21 08:00AM  
Mar-27-21 04:27AM  
Mar-24-21 08:16AM  
Mar-23-21 04:46PM  
Mar-19-21 08:00AM  
Mar-17-21 02:13AM  
Mar-16-21 08:00AM  
Mar-15-21 08:00AM  
Mar-11-21 11:45AM  
Mar-10-21 08:00AM  
Feb-25-21 08:00AM  
Feb-12-21 01:55PM  
Feb-11-21 08:00AM  
Feb-09-21 08:00AM  
Feb-04-21 11:53AM  
Jan-25-21 08:00AM  
Jan-22-21 08:00AM  
Jan-14-21 08:00AM  
Jan-07-21 07:00AM  
Jan-04-21 04:15PM  
Dec-21-20 07:00AM  
Dec-02-20 10:48PM  
Nov-12-20 04:05PM  
Nov-11-20 07:00AM  
Nov-10-20 07:00AM  
Nov-05-20 12:30PM  
Oct-29-20 07:00AM  
Oct-27-20 07:00AM  
Oct-26-20 07:00AM  
Oct-07-20 08:00AM  
Sep-21-20 08:35AM  
Sep-15-20 07:00AM  
Sep-14-20 08:35AM  
Sep-09-20 07:00AM  
Sep-02-20 07:00AM  
Sep-01-20 03:30PM  
Aug-13-20 05:15PM  
Aug-11-20 07:00AM  
Aug-06-20 08:01AM  
Aug-05-20 12:30PM  
Jun-22-20 04:52PM  
Jun-17-20 05:01PM  
Jun-15-20 07:00AM  
Jun-12-20 12:00PM  
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHIMMEL PAULDirectorSep 20Buy8.00250,0002,000,000252,890Sep 22 08:19 PM
CLARKE JOHN KDirectorMay 21Sale4.342,50010,850108,083May 25 09:05 PM
SCHIMMEL PAULDirectorMay 18Buy3.9850,000199,000113,023May 20 08:55 AM
Shukla SanjayPresident and CEOMay 18Buy4.0110,00040,10018,298May 20 08:52 AM
Broadfoot Jill MarieChief Financial OfficerFeb 09Sale7.663902,9879,833Feb 09 09:15 PM
Shukla SanjayPresident and CEOFeb 09Sale7.667785,9598,298Feb 09 09:12 PM